Concepts (127)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Protein Kinase C | 4 | 2019 | 1202 | 0.580 |
Why?
|
| Protein Kinase Inhibitors | 4 | 2016 | 5696 | 0.220 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 3 | 2016 | 1624 | 0.220 |
Why?
|
| Pyrimidines | 2 | 2017 | 3047 | 0.200 |
Why?
|
| Angiogenic Proteins | 1 | 2019 | 101 | 0.150 |
Why?
|
| Prostatic Neoplasms | 2 | 2019 | 11083 | 0.120 |
Why?
|
| G2 Phase | 1 | 2013 | 135 | 0.110 |
Why?
|
| Thiazepines | 1 | 2012 | 30 | 0.100 |
Why?
|
| Lymphoma, Large-Cell, Anaplastic | 1 | 2014 | 169 | 0.100 |
Why?
|
| Antineoplastic Agents | 3 | 2017 | 13648 | 0.100 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 3 | 2016 | 5389 | 0.100 |
Why?
|
| Genomic Instability | 1 | 2017 | 718 | 0.100 |
Why?
|
| Class I Phosphatidylinositol 3-Kinases | 1 | 2017 | 904 | 0.100 |
Why?
|
| ras Proteins | 2 | 2014 | 1053 | 0.100 |
Why?
|
| Cell Line, Tumor | 7 | 2019 | 17075 | 0.090 |
Why?
|
| Epithelial-Mesenchymal Transition | 1 | 2016 | 752 | 0.090 |
Why?
|
| Nucleic Acid Amplification Techniques | 1 | 2013 | 335 | 0.090 |
Why?
|
| Heterocyclic Compounds, 3-Ring | 1 | 2012 | 295 | 0.080 |
Why?
|
| Neovascularization, Pathologic | 1 | 2019 | 2631 | 0.080 |
Why?
|
| DNA Breaks, Double-Stranded | 1 | 2013 | 604 | 0.070 |
Why?
|
| Cell Proliferation | 2 | 2014 | 10429 | 0.070 |
Why?
|
| Structure-Activity Relationship | 1 | 2013 | 3051 | 0.070 |
Why?
|
| Cancer Vaccines | 1 | 2015 | 1044 | 0.070 |
Why?
|
| Xenograft Model Antitumor Assays | 4 | 2019 | 3608 | 0.070 |
Why?
|
| RNA-Binding Proteins | 1 | 2016 | 1874 | 0.070 |
Why?
|
| Cell Division | 1 | 2013 | 4475 | 0.060 |
Why?
|
| B-Lymphocytes | 1 | 2017 | 4778 | 0.050 |
Why?
|
| Signal Transduction | 3 | 2016 | 23600 | 0.050 |
Why?
|
| Cell Movement | 1 | 2013 | 5194 | 0.050 |
Why?
|
| Lung Neoplasms | 2 | 2016 | 13451 | 0.050 |
Why?
|
| Mice, Inbred NOD | 2 | 2016 | 1837 | 0.040 |
Why?
|
| Carcinoma, Renal Cell | 1 | 2015 | 3181 | 0.040 |
Why?
|
| Mice, SCID | 2 | 2016 | 2630 | 0.040 |
Why?
|
| Chemokine CCL11 | 1 | 2019 | 127 | 0.040 |
Why?
|
| Kidney Neoplasms | 1 | 2015 | 4274 | 0.040 |
Why?
|
| Stem Cell Factor | 1 | 2019 | 194 | 0.040 |
Why?
|
| Chemokine CCL5 | 1 | 2019 | 213 | 0.040 |
Why?
|
| Transcription Factor RelA | 1 | 2019 | 252 | 0.040 |
Why?
|
| Transcription Factor AP-1 | 1 | 2019 | 322 | 0.040 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2015 | 9373 | 0.030 |
Why?
|
| Genomics | 1 | 2013 | 5929 | 0.030 |
Why?
|
| Somatic Hypermutation, Immunoglobulin | 1 | 2017 | 102 | 0.030 |
Why?
|
| Gene Expression Regulation, Neoplastic | 3 | 2019 | 8611 | 0.030 |
Why?
|
| Mice | 7 | 2019 | 81818 | 0.030 |
Why?
|
| Leukocyte Disorders | 1 | 2015 | 11 | 0.030 |
Why?
|
| Pyrazoles | 2 | 2017 | 2033 | 0.030 |
Why?
|
| Vimentin | 1 | 2016 | 258 | 0.030 |
Why?
|
| Isoquinolines | 1 | 2017 | 350 | 0.030 |
Why?
|
| Quinazolinones | 1 | 2017 | 219 | 0.030 |
Why?
|
| Immunoglobulin Class Switching | 1 | 2017 | 289 | 0.030 |
Why?
|
| Cytidine Deaminase | 1 | 2017 | 250 | 0.030 |
Why?
|
| Lymphoma, Mantle-Cell | 1 | 2017 | 238 | 0.030 |
Why?
|
| Immunoglobulin Heavy Chains | 1 | 2017 | 648 | 0.030 |
Why?
|
| Tumor Microenvironment | 2 | 2019 | 3946 | 0.030 |
Why?
|
| Protein Binding | 2 | 2019 | 9296 | 0.030 |
Why?
|
| Protein Kinase C-delta | 1 | 2014 | 115 | 0.030 |
Why?
|
| Aphidicolin | 1 | 2013 | 37 | 0.030 |
Why?
|
| Purines | 1 | 2017 | 615 | 0.030 |
Why?
|
| Animals | 8 | 2019 | 168759 | 0.030 |
Why?
|
| Physical Chromosome Mapping | 1 | 2013 | 183 | 0.030 |
Why?
|
| Recombination, Genetic | 1 | 2017 | 1525 | 0.020 |
Why?
|
| MAP Kinase Signaling System | 1 | 2019 | 1490 | 0.020 |
Why?
|
| Mast Cells | 1 | 2019 | 1412 | 0.020 |
Why?
|
| Leukocyte Count | 1 | 2015 | 1602 | 0.020 |
Why?
|
| Cadherins | 1 | 2016 | 900 | 0.020 |
Why?
|
| Chromatin Immunoprecipitation | 1 | 2014 | 857 | 0.020 |
Why?
|
| Translocation, Genetic | 1 | 2017 | 1394 | 0.020 |
Why?
|
| Adenine | 1 | 2017 | 994 | 0.020 |
Why?
|
| Microtubule-Associated Proteins | 1 | 2016 | 1066 | 0.020 |
Why?
|
| Serine Endopeptidases | 1 | 2016 | 1024 | 0.020 |
Why?
|
| Immunoblotting | 1 | 2014 | 1644 | 0.020 |
Why?
|
| Prostate | 1 | 2019 | 1755 | 0.020 |
Why?
|
| Microsatellite Repeats | 1 | 2013 | 784 | 0.020 |
Why?
|
| Hypoxia-Inducible Factor 1, alpha Subunit | 1 | 2014 | 618 | 0.020 |
Why?
|
| DNA Primers | 1 | 2014 | 2825 | 0.020 |
Why?
|
| Testis | 1 | 2013 | 780 | 0.020 |
Why?
|
| Chromatography, High Pressure Liquid | 1 | 2012 | 1526 | 0.020 |
Why?
|
| Down-Regulation | 1 | 2016 | 2927 | 0.020 |
Why?
|
| Tissue Distribution | 1 | 2012 | 2266 | 0.020 |
Why?
|
| Basic Helix-Loop-Helix Transcription Factors | 1 | 2014 | 1140 | 0.020 |
Why?
|
| Transfection | 1 | 2016 | 5743 | 0.020 |
Why?
|
| Piperidines | 1 | 2017 | 1664 | 0.020 |
Why?
|
| Phosphorylation | 1 | 2019 | 8278 | 0.020 |
Why?
|
| Protein-Tyrosine Kinases | 1 | 2017 | 2423 | 0.020 |
Why?
|
| Promoter Regions, Genetic | 1 | 2019 | 5786 | 0.020 |
Why?
|
| RNA Interference | 1 | 2016 | 2832 | 0.020 |
Why?
|
| Cloning, Molecular | 1 | 2013 | 4165 | 0.020 |
Why?
|
| Lymphocytes | 1 | 2015 | 2599 | 0.020 |
Why?
|
| Phosphatidylinositol 3-Kinases | 1 | 2017 | 2878 | 0.020 |
Why?
|
| Humans | 10 | 2019 | 765956 | 0.020 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2014 | 3807 | 0.020 |
Why?
|
| Spleen | 1 | 2013 | 2296 | 0.020 |
Why?
|
| Mice, Inbred BALB C | 1 | 2015 | 6220 | 0.020 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 1 | 2014 | 1761 | 0.020 |
Why?
|
| Enzyme Inhibitors | 1 | 2017 | 3715 | 0.020 |
Why?
|
| Tandem Mass Spectrometry | 1 | 2012 | 1192 | 0.020 |
Why?
|
| Preoperative Care | 1 | 2015 | 2267 | 0.020 |
Why?
|
| Reactive Oxygen Species | 1 | 2014 | 2140 | 0.020 |
Why?
|
| DNA Replication | 1 | 2013 | 1433 | 0.020 |
Why?
|
| Antigens, CD | 1 | 2016 | 4025 | 0.020 |
Why?
|
| Leukemia, Lymphocytic, Chronic, B-Cell | 1 | 2017 | 1646 | 0.020 |
Why?
|
| Virus Replication | 1 | 2013 | 2447 | 0.010 |
Why?
|
| Disease-Free Survival | 1 | 2015 | 6832 | 0.010 |
Why?
|
| RNA, Small Interfering | 1 | 2014 | 3421 | 0.010 |
Why?
|
| Cell Cycle Proteins | 1 | 2016 | 3430 | 0.010 |
Why?
|
| Male | 4 | 2019 | 363691 | 0.010 |
Why?
|
| Neoplasm Metastasis | 1 | 2014 | 4893 | 0.010 |
Why?
|
| Pyridines | 1 | 2015 | 2888 | 0.010 |
Why?
|
| Vaccination | 1 | 2015 | 3426 | 0.010 |
Why?
|
| Mice, Transgenic | 1 | 2015 | 9550 | 0.010 |
Why?
|
| Neutrophils | 1 | 2015 | 3776 | 0.010 |
Why?
|
| Boston | 1 | 2015 | 9338 | 0.010 |
Why?
|
| Fibroblasts | 1 | 2013 | 4159 | 0.010 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2014 | 4520 | 0.010 |
Why?
|
| Base Sequence | 1 | 2013 | 12403 | 0.010 |
Why?
|
| Sequence Analysis, DNA | 1 | 2013 | 4772 | 0.010 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2015 | 4642 | 0.010 |
Why?
|
| Sensitivity and Specificity | 1 | 2015 | 14652 | 0.010 |
Why?
|
| Phenotype | 1 | 2016 | 16721 | 0.010 |
Why?
|
| Reproducibility of Results | 1 | 2015 | 20125 | 0.010 |
Why?
|
| Incidence | 1 | 2015 | 21480 | 0.010 |
Why?
|
| Prognosis | 1 | 2015 | 29921 | 0.010 |
Why?
|
| Mice, Inbred C57BL | 1 | 2013 | 22331 | 0.010 |
Why?
|
| Time Factors | 1 | 2016 | 40065 | 0.010 |
Why?
|
| Risk Assessment | 1 | 2015 | 24283 | 0.010 |
Why?
|
| Female | 3 | 2017 | 396101 | 0.010 |
Why?
|
| Middle Aged | 1 | 2015 | 223004 | 0.000 |
Why?
|
Concepts
(127)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(8)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_
Same Department
People in same department with this person.
Explore
_